Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
671
datasets available to search
ShareScore release 0.9.0
Dataset results
671 results for “Renal function;”
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
ClinicalTrials.gov study NCT00997399. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Data from: Hypoglycemia Following intravenous insulin plus glucose for hyperkalemia in patients with impaired renal function
Background: Hypoglycemia is a serious complication following the administration of insulin for hyperkalemia. We determined the incidence of hypoglycemia and severe hypoglycemia (blood glucose <70 or ≤40 mg/dl, respectively) in a cohort of AKI and non-dialysis dependent CKD patients who received an intravenous infusion of insulin plus glucose to treat hyperkalemia. Methods: We retrospectively reviewed charts of all AKI and non-dialysis dependent CKD patients who received 10 U of insulin plus 50 g glucose to treat hyperkalemia from December 1, 2013 to May 31, 2015 at our Department. Results: One hundred sixty four episodes of hyperkalemia were treated with insulin plus glucose and were eligible for analysis. Serum potassium levels dropped by 1.18 ± 1.01 mmol/l. Eleven treatments (6.1%) resulted in hypoglycemia and two (1.2%) in severe hypoglycemia. A lower pretreatment blood glucose tended to associate with a higher subsequent risk of hypoglycemia. Age, sex, renal function, an established diagnosis of diabetes or previous treatment were not associated with the development of this complication. We did not register any significant adverse events. Conclusion: Our intravenous regimen combining an infusion of insulin plus glucose effectively reduced serum potassium levels compared to previous studies and associated a low risk of symptomatic hypoglycemia and other complications.
Data from: Prospective randomized trial comparing hepatic venous outflow and renal function after conventional versus piggyback liver transplantation
Background: This randomized prospective clinical trial compared the hepatic venous outflow drainage and renal function after conventional with venovenous bypass (n = 15) or piggyback (n = 17) liver transplantation. Methods: Free hepatic vein pressure (FHVP) and central venous pressure (CVP) measurements were performed after graft reperfusion. Postoperative serum creatinine (Cr) was measured daily on the first week and on the 14th, 21st and 28th postoperative days (PO). The prevalence of acute renal failure (ARF) up to the 28th PO was analyzed by RIFLE-AKIN criteria. A Generalized Estimating Equation (GEE) approach was used for comparison of longitudinal measurements of renal function. Results: FHVP-CVP gradient > 3 mm Hg was observed in 26.7% (4/15) of the patients in the conventional group and in 17.6% (3/17) in the piggyback group (p = 0.68). Median FHVP-CVP gradient was 2 mm Hg (0–8 mmHg) vs. 3 mm Hg (0–7 mm Hg) in conventional and piggyback groups, respectively (p = 0.73). There is no statistically significant difference between the conventional (1/15) and the piggyback (2/17) groups regarding massive ascites development (p = 1.00). GEE estimated marginal mean for Cr was significantly higher in conventional than in piggyback group (2.14 ± 0.26 vs. 1.47 ± 0.15 mg/dL; p = 0.02). The conventional method presented a higher prevalence of severe ARF during the first 28 PO days (OR = 3.207; 95% CI, 1.010 to 10.179; p = 0.048). Conclusion: Patients submitted to liver transplantation using conventional or piggyback methods present similar results regarding venous outflow drainage of the graft. Conventional with venovenous bypass technique significantly increases the harm of postoperative renal dysfunction.
Data from: Predictive value of apelin-12 in ST-elevation myocardial infarction patients with different renal function: a prospective observational study
Objectives: To investigate the factors predicting the onset of major adverse cardiovascular events (MACEs) after primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) patients. Background: apelin-12 has been regarded acting essential role in cardiovascular homeostasis. However, current knowledge of the optimal prognostic predictive value is limited. Methods: 464 STEMI patients (63.0±11.9 years, 355 men) who underwent successful pPCI were enrolled. Patients were followed-up for 2.5 years. Multivariate cox regression analyses and receiver operating characteristic curve analysis were performed to determine the factors predicting MACEs. Results: There were 118 patients (25.4%) who experienced MACEs in the follow-up period. Multivariate cox regression analysis demonstrated that low apelin-12 (HR=0.132, 95% CI=0.060-0.292, p<0.001), low left ventricular ejection fraction (LVEF) (HR=0.965, 95% CI=0.941-0.991, p=0.007), low estimated glomerular filtration rate (eGFR) (HR=0.985, 95% CI=0.977-0.993, p<0.001), Killip's classification>I (HR=0.610, 95% CI=0.408-0.912, p=0.016) and pathological Q-wave (HR=1.536, 95% CI=1.058-2.230, p=0.024) were independent predictors of 2.5 MACEs. Low apelin-12 could also predict worse in-hospital prognosis and showed advantage in predicting 2.5 year MACEs compared with Δapelin-12 (p=0.0115)and eGFR (p=0.0071) among patients with eGFR>90 mL/min1.73m2. Further analysis prompt Δapelin-12<20% was usually associated with MACEs in patients whose apelin-12 admission below 0.76 ng/ml (p=0.0075). Conclusions: STEMI patients receiving pPCI with lower apelin-12 are more likely to suffer MACEs in hospitalization and 2.5-year follow-up, especially for those with normal level of eGFR.
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
ClinicalTrials.gov study NCT00354458. IPD Sharing: Not stated. Countries: 0. Publications: 13.
Replacement of Lamivudine by Telbivudine to Improve Renal Function
ClinicalTrials.gov study NCT02447705. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Impact of Renal Function Availability to Community Pharmacist for Dispensing Direct Oral Anticoagulant in Ambulatory Patients on Bleeding Occurrence
ClinicalTrials.gov study NCT06739603. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Pulmonary Function Tests in Children and Adolescents With End Stage Renal Disease On Regular Hemodialysis
ClinicalTrials.gov study NCT06106438. IPD Sharing: Not stated. Countries: 0. Publications: 3.
Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
ClinicalTrials.gov study NCT01289080. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function
ClinicalTrials.gov study NCT03442725. IPD Sharing: Not stated. Countries: 4. Publications: 0.
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
ClinicalTrials.gov study NCT04398745. IPD Sharing: YES. Countries: 4. Publications: 0.
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
ClinicalTrials.gov study NCT01830816. IPD Sharing: Not stated. Countries: 2. Publications: 0.
External Validation of IRRIV Test Relationship With Renal Functional Reserve
ClinicalTrials.gov study NCT03756402. IPD Sharing: UNDECIDED. Countries: 0. Publications: 1.
An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil
ClinicalTrials.gov study NCT01672957. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Mixed Cohort, Multicentre Exploratory Study of Non-invasive Quantitative Assessment of Renal Graft Function With Non-contrast Functional Magnetic Resonance Imaging
ClinicalTrials.gov study NCT07333495. IPD Sharing: NO. Countries: 1. Publications: 0.
Effects of Aminophylline on Renal Function and Urine Volume of AKI Patient
ClinicalTrials.gov study NCT02983422. IPD Sharing: Not stated. Countries: 0. Publications: 4.
Impact of Residual Renal Function on Complications in Chronic Hemodialysis Patients
ClinicalTrials.gov study NCT03854513. IPD Sharing: Not stated. Countries: 0. Publications: 4.
Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
ClinicalTrials.gov study NCT03009162. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
ClinicalTrials.gov study NCT01546519. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Recovery of Short-term Renal Function in Post-transplant Patients Living Donor
ClinicalTrials.gov study NCT03717259. IPD Sharing: NO. Countries: 0. Publications: 26.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.